A080720 Stock Overview
Engages in the research, development, production, and sale of prescription drugs in South Korea. More details
Snowflake Score | |
---|---|
Valuation | 2/6 |
Future Growth | 0/6 |
Past Performance | 0/6 |
Financial Health | 3/6 |
Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Union Korea Pharm Co., Ltd. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | ₩2,725.00 |
52 Week High | ₩6,460.00 |
52 Week Low | ₩2,450.00 |
Beta | -0.062 |
1 Month Change | 0% |
3 Month Change | -7.00% |
1 Year Change | -45.50% |
3 Year Change | -72.89% |
5 Year Change | -79.43% |
Change since IPO | -86.03% |
Recent News & Updates
Union Korea Pharm Co., Ltd.'s (KOSDAQ:080720) 26% Share Price Plunge Could Signal Some Risk
Jul 22Is Union Korea Pharm (KOSDAQ:080720) A Risky Investment?
Apr 23Recent updates
Union Korea Pharm Co., Ltd.'s (KOSDAQ:080720) 26% Share Price Plunge Could Signal Some Risk
Jul 22Is Union Korea Pharm (KOSDAQ:080720) A Risky Investment?
Apr 23Union Korea Pharm (KOSDAQ:080720) Is Carrying A Fair Bit Of Debt
Jan 27What Percentage Of Union Korea Pharm Co., Ltd. (KOSDAQ:080720) Shares Do Insiders Own?
Dec 22The Union Korea Pharm (KOSDAQ:080720) Share Price Has Gained 38% And Shareholders Are Hoping For More
Nov 17Shareholder Returns
A080720 | KR Pharmaceuticals | KR Market | |
---|---|---|---|
7D | 0% | 2.2% | -1.5% |
1Y | -45.5% | -3.3% | -10.9% |
Return vs Industry: A080720 underperformed the KR Pharmaceuticals industry which returned -3.3% over the past year.
Return vs Market: A080720 underperformed the KR Market which returned -10.9% over the past year.
Price Volatility
A080720 volatility | |
---|---|
A080720 Average Weekly Movement | n/a |
Pharmaceuticals Industry Average Movement | 5.5% |
Market Average Movement | 6.6% |
10% most volatile stocks in KR Market | 12.8% |
10% least volatile stocks in KR Market | 3.4% |
Stable Share Price: A080720's share price has been volatile over the past 3 months compared to the KR market.
Volatility Over Time: Insufficient data to determine A080720's volatility change over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1956 | 196 | n/a | www.ukp.co.kr |
Union Korea Pharm Co., Ltd. engages in the research, development, production, and sale of prescription drugs in South Korea. It offers pharmaceuticals in various formulations, including tablets, capsules, and injections in the areas of cardiovascular, gastrointestinal, muscular skeletal, antibiotics, etc. The company was formerly known as Union Pharmaceutical Co., Ltd. and changed its name to Union Korea Pharm Co., Ltd.
Union Korea Pharm Co., Ltd. Fundamentals Summary
A080720 fundamental statistics | |
---|---|
Market cap | ₩15.41b |
Earnings (TTM) | -₩20.39b |
Revenue (TTM) | ₩64.09b |
0.2x
P/S Ratio-0.8x
P/E RatioIs A080720 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
A080720 income statement (TTM) | |
---|---|
Revenue | ₩64.09b |
Cost of Revenue | ₩38.55b |
Gross Profit | ₩25.54b |
Other Expenses | ₩45.94b |
Earnings | -₩20.39b |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
Earnings per share (EPS) | -3.61k |
Gross Margin | 39.85% |
Net Profit Margin | -31.81% |
Debt/Equity Ratio | 112.4% |
How did A080720 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
Data | Last Updated (UTC time) |
---|---|
Company Analysis | 2025/01/02 08:41 |
End of Day Share Price | 2024/10/11 00:00 |
Earnings | 2024/09/30 |
Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package | Data | Timeframe | Example US Source * |
---|---|---|---|
Company Financials | 10 years |
| |
Analyst Consensus Estimates | +3 years |
|
|
Market Prices | 30 years |
| |
Ownership | 10 years |
| |
Management | 10 years |
| |
Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Union Korea Pharm Co., Ltd. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst | Institution |
---|